TY - JOUR
T1 - An international collaborative standardizing a comprehensive patient-centered outcomes measurement set for colorectal cancer
AU - Colorectal Cancer Working Group of the International Consortium for Health Outcomes Measurement (ICHOM)
AU - Zerillo, Jessica A.
AU - Schouwenburg, Maartje G.
AU - Van Bommel, Annelotte C.M.
AU - Stowell, Caleb
AU - Lippa, Jacob
AU - Bauer, Donna
AU - Berger, Ann M.
AU - Boland, Gilles
AU - Borras, Josep M.
AU - Buss, Mary K.
AU - Cima, Robert
AU - Van Cutsem, Eric
AU - Van Duyn, Eino B.
AU - Finlayson, Samuel R.G.
AU - Cheng, Skye Hung Chun
AU - Langelotz, Corinna
AU - Lloyd, John
AU - Lynch, Andrew C.
AU - Mamon, Harvey J.
AU - McAllister, Pamela K.
AU - Minsky, Bruce D.
AU - Ngeow, Joanne
AU - Abu Hassan, Muhammad R.
AU - Ryan, Kim
AU - Shankaran, Veena
AU - Upton, Melissa P.
AU - Zalcberg, John
AU - Van De Velde, Cornelis J.
AU - Tollenaar, Rob
N1 - Funding Information:
Dr Lynch reported receiving a grant from Fisher and Paykel and honoraria from Olympus and Device Technologies. Dr Mamon reported receiving personal fees from UpToDate, Oakstone Publishing, and Cerulean Pharmaceuticals. Dr McAllister reported receiving a nominal salary from the National Cancer Institute Gastrointestinal Steering Committee and reported doing unpaid work for the American Society of Clinical Oncology, the American Cancer Society, and the American Society for Clinical Pathology. Dr Ngeow reported being supported by the National Medical Research Council Singapore. Dr Shankaran reported receiving grants from Merck and Bayer. Dr Upton reported receiving grants from the National Institutes of Health, the National Science Foundation, and the University of Washington and reported receiving article fees from the American Journal of Clinical Pathology.No other disclosures were reported. This work was supported by Bowel Cancer Australia, Centraal Ziekenfonds, the Dutch Institute for Clinical Auditing, and the American Society for Clinical Pathology.
Publisher Copyright:
Copyright 2017 American Medical Association. All rights reserved.
PY - 2017/5/1
Y1 - 2017/5/1
N2 - IMPORTANCE: Global health systems are shifting toward value-based care in an effort to drive better outcomes in the setting of rising health care costs. This shift requires a common definition of value, starting with the outcomes that matter most to patients. OBJECTIVE: The International Consortium for Health Outcomes Measurement (ICHOM), a nonprofit initiative, was formed to define standard sets of outcomes by medical condition. In this article, we report the efforts of ICHOM's working group in colorectal cancer. EVIDENCE REVIEW: The working group was composed of multidisciplinary oncology specialists in medicine, surgery, radiation therapy, palliative care, nursing, and pathology, along with patient representatives. Through a modified Delphi process during 8 months (July 8, 2015 to February 29, 2016), ICHOM led the working group to a consensus on a final recommended standard set. The process was supported by a systematic PubMed literature review (1042 randomized clinical trials and guidelines from June 3, 2005, to June 3, 2015), a patient focus group (11 patients with early and metastatic colorectal cancer convened during a teleconference in August 2015), and a patient validation survey (among 276 patients with and survivors of colorectal cancer between October 15, 2015, and November 4, 2015). FINDINGS: After consolidating findings of the literature review and focus group meeting, a list of 40 outcomes was presented to the WG and underwent voting. The final recommendation includes outcomes in the following categories: survival and disease control, disutility of care, degree of health, and quality of death. Selected case-mix factors were recommended to be collected at baseline to facilitate comparison of results across treatments and health care professionals. CONCLUSIONS: A standardized set of patient-centered outcome measures to inform value-based health care in colorectal cancer was developed. Pilot efforts are under way to measure the standard set among members of the working group.
AB - IMPORTANCE: Global health systems are shifting toward value-based care in an effort to drive better outcomes in the setting of rising health care costs. This shift requires a common definition of value, starting with the outcomes that matter most to patients. OBJECTIVE: The International Consortium for Health Outcomes Measurement (ICHOM), a nonprofit initiative, was formed to define standard sets of outcomes by medical condition. In this article, we report the efforts of ICHOM's working group in colorectal cancer. EVIDENCE REVIEW: The working group was composed of multidisciplinary oncology specialists in medicine, surgery, radiation therapy, palliative care, nursing, and pathology, along with patient representatives. Through a modified Delphi process during 8 months (July 8, 2015 to February 29, 2016), ICHOM led the working group to a consensus on a final recommended standard set. The process was supported by a systematic PubMed literature review (1042 randomized clinical trials and guidelines from June 3, 2005, to June 3, 2015), a patient focus group (11 patients with early and metastatic colorectal cancer convened during a teleconference in August 2015), and a patient validation survey (among 276 patients with and survivors of colorectal cancer between October 15, 2015, and November 4, 2015). FINDINGS: After consolidating findings of the literature review and focus group meeting, a list of 40 outcomes was presented to the WG and underwent voting. The final recommendation includes outcomes in the following categories: survival and disease control, disutility of care, degree of health, and quality of death. Selected case-mix factors were recommended to be collected at baseline to facilitate comparison of results across treatments and health care professionals. CONCLUSIONS: A standardized set of patient-centered outcome measures to inform value-based health care in colorectal cancer was developed. Pilot efforts are under way to measure the standard set among members of the working group.
UR - http://www.scopus.com/inward/record.url?scp=85020082456&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85020082456&partnerID=8YFLogxK
U2 - 10.1001/jamaoncol.2017.0417
DO - 10.1001/jamaoncol.2017.0417
M3 - Review article
C2 - 28384684
AN - SCOPUS:85020082456
VL - 3
SP - 686
EP - 694
JO - JAMA oncology
JF - JAMA oncology
SN - 2374-2437
IS - 5
ER -